Perioperative novel systemic immunotherapy-based approaches in urinary cancers

Bookmark and Share
Published: 9 Jun 2020
Views: 538
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA

Dr Shilpa Gupta talks to ecancer in an online interview at the virtual ASCO meeting 2020 about the role of perioperative systemic immunotherapy in patients with urothelial cancer based on four abstracts.

The four trials are:

GU14-188 - Neoadjuvant gemcitabine and pembrolizumab prior to cystectomy in patients with cT2-4aN0M0 urothelial carcinoma.

NABUCCO - Neoadjuvant use of checkpoint inhibitor monotherapy (pembrolizumab or atezolizumab).

Neoadjuvant/adjuvant durvalumab with/without tremelimumab in renal cell carcinoma (RCC).

SWOG S1605 - Checkpoint inhibition using atezolizumab in Bacillus Calmette-Guérin (BCG) refractory nonmuscle-invasive bladder cancer.